Merit Medical Adds View Point in $140M Deal to Deepen Oncology Portfolio

Merit Medical Systems (NASDAQ: MMSI) is acquiring privately held View Point Medical in a deal valued at 140 million dollars, consisting of 90 million dollars upfront and two follow‑on payments totaling 50 million dollars on the first and second anniversaries of closing. Merit expects the acquisition to contribute about 14–16 million dollars in revenue in 2027, adding a new growth driver within its oncology and interventional portfolio.

 Tumor localization products fit existing platform

View Point sells the FDA‑cleared OneMark Detection Imaging System and OneMark Tissue Markers, used to localize tumor tissue during biopsies and cancer resection surgeries with ultrasound guidance. These products slot alongside Merit’s existing SCOUT wire‑free localization platform, which uses an external probe and does not require ultrasound, giving surgeons complementary options depending on imaging workflow and site capabilities.

 Strategic rationale and clinical positioning

Needham analysts noted it will be rare for clinicians to use both OneMark and SCOUT in the same patient, but see the acquisition as expanding Merit’s toolbox of wire‑free breast tumor localization technologies, especially in centers where ultrasound is already deeply embedded. The deal is consistent with Merit’s tuck‑in M&A strategy focused on platforms; management has emphasized using cross‑functional, cross‑geography teams to identify targets that “fill a rep’s bag” and leverage existing commercial channels.

 Ongoing roll‑up in adjacent niches

View Point continues a string of targeted acquisitions by Merit, including EndoGastric Solutions for 105 million dollars and Cook Medical’s lead management portfolio for about 210 million dollars in 2024, as well as Biolife and the C2 CryoBalloon line in earlier transactions. For MMSI shareholders, these deals collectively broaden the company’s presence in higher‑growth, procedure‑centric niches, support incremental cross‑selling, and reinforce a capital allocation strategy built around bolt‑ons rather than large, binary bets.